MA39347A1 - Protéines de fusion d'uti - Google Patents

Protéines de fusion d'uti

Info

Publication number
MA39347A1
MA39347A1 MA39347A MA39347A MA39347A1 MA 39347 A1 MA39347 A1 MA 39347A1 MA 39347 A MA39347 A MA 39347A MA 39347 A MA39347 A MA 39347A MA 39347 A1 MA39347 A1 MA 39347A1
Authority
MA
Morocco
Prior art keywords
fusion proteins
uti fusion
uti
proteins
producing
Prior art date
Application number
MA39347A
Other languages
English (en)
Other versions
MA39347B2 (fr
Inventor
Aaron Chamberlain
Qiang Liu
Mathias Schmidt
Original Assignee
Takeda Pharmaceuticals Co
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co, Takeda Gmbh filed Critical Takeda Pharmaceuticals Co
Publication of MA39347A1 publication Critical patent/MA39347A1/fr
Publication of MA39347B2 publication Critical patent/MA39347B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des protéines de fusion d'uti, des séquences d'adn pour produire ces protéines, et des compositions pharmaceutiques et des méthodes d'utilisation correspondantes.
MA39347A 2014-02-24 2015-02-23 Protéines de fusion d'uti MA39347B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461943617P 2014-02-24 2014-02-24
PCT/US2015/017152 WO2015127391A1 (fr) 2014-02-24 2015-02-23 Protéines de fusion d'uti

Publications (2)

Publication Number Publication Date
MA39347A1 true MA39347A1 (fr) 2018-06-29
MA39347B2 MA39347B2 (fr) 2020-05-29

Family

ID=52629709

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39347A MA39347B2 (fr) 2014-02-24 2015-02-23 Protéines de fusion d'uti

Country Status (38)

Country Link
US (4) US9856310B2 (fr)
EP (2) EP3443978A1 (fr)
JP (4) JP6574431B2 (fr)
KR (3) KR102461210B1 (fr)
CN (2) CN106232135B (fr)
AR (1) AR101597A1 (fr)
AU (4) AU2015218704B2 (fr)
BR (1) BR112016019390B1 (fr)
CA (2) CA2939639C (fr)
CL (1) CL2016002136A1 (fr)
CR (1) CR20160444A (fr)
CY (1) CY1120997T1 (fr)
DK (1) DK3110434T3 (fr)
DO (1) DOP2016000202A (fr)
EA (2) EA202091567A1 (fr)
EC (1) ECSP16076535A (fr)
ES (1) ES2700149T3 (fr)
GE (2) GEAP201814277A (fr)
HR (1) HRP20182029T1 (fr)
IL (1) IL247321B (fr)
JO (1) JO3729B1 (fr)
LT (1) LT3110434T (fr)
MA (1) MA39347B2 (fr)
MX (4) MX2016010950A (fr)
MY (1) MY178774A (fr)
NZ (3) NZ724196A (fr)
PE (1) PE20170257A1 (fr)
PH (1) PH12016501629B1 (fr)
PL (1) PL3110434T3 (fr)
PT (1) PT3110434T (fr)
RS (1) RS58285B1 (fr)
SG (2) SG11201606691QA (fr)
SI (1) SI3110434T1 (fr)
SM (1) SMT201800674T1 (fr)
TW (1) TWI694084B (fr)
UA (1) UA118866C2 (fr)
WO (1) WO2015127391A1 (fr)
ZA (1) ZA201606327B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA39347B2 (fr) * 2014-02-24 2020-05-29 Takeda Pharmaceuticals Co Protéines de fusion d'uti
KR20250030036A (ko) * 2017-06-07 2025-03-05 스파크 테라퓨틱스, 인코포레이티드 개선된 세포 트랜스펙션 및/또는 rAAV 벡터 생산을 위한 증진제
WO2020106881A1 (fr) * 2018-11-20 2020-05-28 Diamedica Inc. Polypeptides d'ulinastatine modifiés
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
BR112022017718A2 (pt) * 2020-03-05 2022-11-16 Diamedica Usa Inc Polipeptídeos de ulinastatina
JP2024505073A (ja) * 2021-01-29 2024-02-02 ダイアメディカ ユーエスエー インコーポレイテッド 疾患を処置するためのウリナスタチンポリペプチド
CN116903721A (zh) * 2023-06-16 2023-10-20 成都佩德生物医药有限公司 多肽pdbpe-001、其药物组合物和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
ES2066033T3 (es) 1989-05-13 1995-03-01 Bayer Ag Inhibidores de las proteinasas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
CA2055425A1 (fr) 1990-11-13 1992-05-14 Hideaki Morishita Polypeptide, fragment d'adn l'encodant, methode pour le fabriquer, procede d'inhibition enzymatique, composition medicamenteuse et methodes de traitement faisant appel a ce
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
WO1997033996A2 (fr) 1996-03-11 1997-09-18 Bayer Corporation Bikunine humaine
DE19725014A1 (de) 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
SI1730191T1 (sl) * 2004-03-30 2011-11-30 Glaxo Group Ltd Imunoglobulin-vezavni hOSM
CA2578613A1 (fr) 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Proteines de fusion a domaine de liaison
WO2006129849A1 (fr) * 2005-06-03 2006-12-07 Mochida Pharmaceutical Co., Ltd. Proteine fusionnee possedant un anticorps anti-cd14
US8828703B2 (en) 2005-12-29 2014-09-09 Dyax Corp. Protease inhibition
WO2010035012A1 (fr) * 2008-09-26 2010-04-01 Ucb Pharma S.A. Produits biologiques
CN102580085B (zh) * 2008-10-13 2013-09-18 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗脓毒症药物中的应用
CN101721699B (zh) * 2008-10-13 2012-11-07 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用
US20120052069A1 (en) * 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
PL3053932T3 (pl) * 2010-02-19 2021-03-08 Xencor, Inc. Nowe immunoadhezyny CTLA4-IG
PH12013502441B1 (en) * 2011-04-29 2019-02-08 Univ Washington Therapeutic nuclease compositions and methods
US8619331B2 (en) 2011-07-19 2013-12-31 Xerox Corporation Simulated paper texture using clear toner and glossmark on texture-less stock
JP6138815B2 (ja) * 2011-12-01 2017-05-31 エーピー バイオサイエンシーズ， インコーポレイテッド 補体経路およびｖｅｇｆ経路に対するタンパク質インヒビターおよびそれらの使用方法
WO2013162050A1 (fr) * 2012-04-23 2013-10-31 株式会社Ｎｒｌファーマ Protéine de fusion à base de lactoferrine et son procédé de production
JP2013253079A (ja) * 2012-05-14 2013-12-19 Xuhua (Shanghai) Biological Research & Development Center Co Ltd 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用
CN103044554B (zh) 2012-05-14 2014-08-27 旭华（上海）生物研发中心有限公司 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
MA39347B2 (fr) * 2014-02-24 2020-05-29 Takeda Pharmaceuticals Co Protéines de fusion d'uti

Also Published As

Publication number Publication date
JP2017512058A (ja) 2017-05-18
TWI694084B (zh) 2020-05-21
US9856310B2 (en) 2018-01-02
SG11201606691QA (en) 2016-09-29
CN110092837B (zh) 2024-01-02
GEP20196970B (en) 2019-04-25
EP3443978A1 (fr) 2019-02-20
US20220127334A1 (en) 2022-04-28
US20160362475A1 (en) 2016-12-15
TW201630931A (zh) 2016-09-01
UA118866C2 (uk) 2019-03-25
MX2016010950A (es) 2017-04-25
CR20160444A (es) 2017-04-21
US20180072795A1 (en) 2018-03-15
AU2023200875A1 (en) 2023-04-27
EA202091567A1 (ru) 2021-07-30
GEAP201814277A (en) 2018-12-25
PH12016501629A1 (en) 2017-02-06
NZ724196A (en) 2022-01-28
RS58285B1 (sr) 2019-03-29
CN106232135A (zh) 2016-12-14
NZ760008A (en) 2023-03-31
CA2939639A1 (fr) 2015-08-27
KR20240155987A (ko) 2024-10-29
IL247321B (en) 2020-06-30
KR20220151005A (ko) 2022-11-11
PH12016501629B1 (en) 2023-10-20
AR101597A1 (es) 2016-12-28
DK3110434T3 (en) 2019-01-14
BR112016019390B1 (pt) 2023-11-14
US10351618B2 (en) 2019-07-16
WO2015127391A1 (fr) 2015-08-27
CN106232135B (zh) 2019-12-10
MY178774A (en) 2020-10-20
MX2019013124A (es) 2020-08-31
KR20160141718A (ko) 2016-12-09
CL2016002136A1 (es) 2017-08-11
JP2022002513A (ja) 2022-01-11
NZ760789A (en) 2023-03-31
JP2023123763A (ja) 2023-09-05
SMT201800674T1 (it) 2019-01-11
BR112016019390A2 (pt) 2017-10-24
AU2021225156A1 (en) 2021-09-30
JO3729B1 (ar) 2021-01-31
IL247321A0 (en) 2016-09-29
AU2019204448B2 (en) 2021-06-10
DOP2016000202A (es) 2016-12-15
LT3110434T (lt) 2018-12-27
AU2015218704B2 (en) 2019-05-02
JP2019187427A (ja) 2019-10-31
SI3110434T1 (sl) 2019-02-28
MX384070B (es) 2025-03-14
CN110092837A (zh) 2019-08-06
JP6574431B2 (ja) 2019-09-11
MX2024000004A (es) 2024-02-20
US20200040062A1 (en) 2020-02-06
EP3110434B1 (fr) 2018-09-19
PE20170257A1 (es) 2017-03-30
JP6938565B2 (ja) 2021-09-22
EA201691702A1 (ru) 2017-01-30
CA3178241A1 (fr) 2015-08-27
SG10201708400QA (en) 2017-11-29
EP3110434A1 (fr) 2017-01-04
KR102722304B1 (ko) 2024-10-28
ECSP16076535A (es) 2017-08-31
KR102461210B1 (ko) 2022-10-31
MA39347B2 (fr) 2020-05-29
AU2021225156B2 (en) 2022-11-24
ZA201606327B (en) 2019-01-30
PT3110434T (pt) 2018-12-19
AU2015218704A1 (en) 2016-09-22
PL3110434T3 (pl) 2019-01-31
AU2019204448A1 (en) 2019-07-11
EA037256B1 (ru) 2021-02-26
CY1120997T1 (el) 2019-12-11
CA2939639C (fr) 2023-01-24
ES2700149T3 (es) 2019-02-14
HRP20182029T1 (hr) 2019-02-08

Similar Documents

Publication Publication Date Title
MA39347B2 (fr) Protéines de fusion d'uti
IL268856A (en) Methods for purification of messenger rna
EP3679141C0 (fr) Méthodes et compositions pour inhiber l'expression de la ldha
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
MA40938A (fr) Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
EA202092435A2 (ru) Моноклональные антитела против bcma
MY193728A (en) Muscarinic receptor agonists
MA40534A (fr) Inhibiteurs de mk2 et leurs utilisations
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
CY1119489T1 (el) Υποκατεστημενη πιπεριδυλο-αιθυλο-πυριμιδινη ως αναστολεας της ο-ακυλο τρανσφερασης της γκρελινης
MA44008A (fr) 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201600122A1 (ru) Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
SG10201806454RA (en) Anti-tenascin c antibodies and uses thereof
WO2016138538A3 (fr) Utilisation thérapeutique d'anticorps de liaison à l'intégrine
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
UA117779C2 (uk) Піразини як модулятори gpr6
EA201691493A1 (ru) Замещенные n-арилпиридиноны
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
EA201692227A1 (ru) Производные сложных аминоэфиров
EP3387431A4 (fr) Systèmes, méthodes et compositions pour améliorer la spécificité de l'hybridation des acides nucléiques
MX2017013222A (es) Derivados de acido (s)-2'-vinil-abscisico.